newsfilter
← Latest News
GlobeNewswire·

VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL study expected in the second half of 2022 More than